The increasing incidence of chronic radia− tion proctitis (CRP) is due to the increas− ing use of radiotherapy in prostate cancer. The incidence ranges between 2 % and 20 % in various retrospective studies. Me− dian time to clinical symptoms ranges from 8 to 13 months [1] . Argon plasma coagulation (APC) has now been estab− lished as an effective, safe, and well−toler− ated endoscopic therapy, with success rates between 80 % and 100 % [2] . The dose±volume toxicity is a well−proven factor in rectal bleeding. Intensity−modu− lated radiotherapy (IMRT) has reduced the overall rectal toxicity, but rectal le− sions induced by IMRT often begin right above the anus [3] . The use of APC is diffi− cult for lesions located immediately above the dentate line in the upper part of the anal canal. These can generally only be approached in the retroflexed po− sition. Disadvantages include a higher risk of rectal scarring, less mobility of the endoscope, and greater patient discom− fort. The use of a transparent cap at the tip of the colonoscope allows direct viewing of low rectal lesions and of the upper part of the anal canal without the retroflexed position (l " Fig. 1 ). Visualization of lesions right above the dentate line is facilitated by displacement of mucosal folds without obscuring the lumen (l " Fig. 2 and Video 1). Stability is maintained by placing the tip of the endoscope against the mucosa, thus allowing safe APC. Thanks to the cap, the endoscope remains close to the lesion, but not too close to it. From November 2007 to March 2008, we treated seven patients for CRP with APC using a transparent cap. Sessions were performed without sedation and were well tolerated by all patients, with no short−term complications. In conclusion, using IMRT for prostate cancer increases low rectal toxicity that can be easily man− aged by APC with a transparent cap at− tached to the tip of the colonoscope. This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
